UF Hepatology Research at CTRB
Welcome,         Profile    Billing    Logout  
 7 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Szczech, Lynda Anne
NCT06121375: Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Recruiting
2/3
144
RoW
OCA, Matching Placebo
Intercept Pharmaceuticals
Biliary Atresia
12/27
12/27
NCT02887859: Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

Completed
2
15
US
Human Acellular Vessel (HAV)
Humacyte, Inc., Atlantic Research Group
Peripheral Artery Disease
12/20
12/23
NCT04135417 / 2018-003570-26: Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis

Completed
2
30
Europe
HAV
Humacyte, Inc., Humacyte, Inc.
Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis
05/21
03/22
CARE, NCT05321524 / 2014-004693-42: Obeticholic Acid in Pediatric Subjects With Biliary Atresia

Terminated
2
7
Europe, RoW
OCA 0.1mg, Obeticholic Acid, 6alpha-ethylchenodeoxycholic acid (6-ECDCA), INT-747, OCA 1.5mg, OCA 5mg
Intercept Pharmaceuticals
Biliary Atresia
03/23
03/23
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
HEROES PBC, NCT05293938: A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

Withdrawn
N/A
2350
US
Obeticholic Acid 5 MG, Ocaliva, Obeticholic Acid 10 MG, Standard of Care: UDCA
Intercept Pharmaceuticals, Global PBC Study Group, Target RWE, Syneos Health, UK PBC Study Group
Primary Biliary Cholangitis
06/23
07/23
Firpi-Morell, Roberto J
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
ALTA TIPS, NCT03973372: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

Recruiting
N/A
1000
US
University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
07/25
12/27
Foerman, Briana
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis

Active, not recruiting
1/2
42
US
CNP-104, Placebo
COUR Pharmaceutical Development Company, Inc.
Primary Biliary Cholangitis
01/26
01/26
ALTA TIPS, NCT03973372: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement

Recruiting
N/A
1000
US
University of Texas Southwestern Medical Center, University of California, San Francisco, Scripps Health, University of Wisconsin, Madison, University of Florida, University of Arizona, Stanford University, Columbia University, Weill Medical College of Cornell University, Baylor Scott and White Health, Mayo Clinic, University of Chicago, Digestive Health Foundation, W.L.Gore & Associates, University of Minnesota, Northwestern University
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
07/25
12/27
McClellan, Lasheaka
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Recruiting
N/A
2500
US
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Exact Sciences Corporation
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
01/25
04/26
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Surow, Julia
VANTAGE, NCT05050136 / 2021-001389-39: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, Canada, Japan, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25

Download Options